Cargando…
Cross-Antigenicity between EV71 Sub-Genotypes: Implications for Vaccine Efficacy
Enterovirus A-71 (EV71) is a global, highly contagkkious pathogen responsible for severe cases of hand-food-mouth-disease (HFMD). The use of vaccines eliciting cross neutralizing antibodies (NTAbs) against the different circulating EV71 sub-genotypes is important for preventing HFMD outbreaks. Here,...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8143144/ https://www.ncbi.nlm.nih.gov/pubmed/33919184 http://dx.doi.org/10.3390/v13050720 |
_version_ | 1783696698496778240 |
---|---|
author | Liu, Pei Yuan, Yadi Cui, Bopei Huo, Yaqian Bian, Lianlian Chen, Lei Liu, Siyuan Wang, Chenfei Xu, Yingzhi Tedcastle, Alison Gao, Fan Mao, Qunying Martin, Javier Liang, Zhenglun |
author_facet | Liu, Pei Yuan, Yadi Cui, Bopei Huo, Yaqian Bian, Lianlian Chen, Lei Liu, Siyuan Wang, Chenfei Xu, Yingzhi Tedcastle, Alison Gao, Fan Mao, Qunying Martin, Javier Liang, Zhenglun |
author_sort | Liu, Pei |
collection | PubMed |
description | Enterovirus A-71 (EV71) is a global, highly contagkkious pathogen responsible for severe cases of hand-food-mouth-disease (HFMD). The use of vaccines eliciting cross neutralizing antibodies (NTAbs) against the different circulating EV71 sub-genotypes is important for preventing HFMD outbreaks. Here, we tested the cross-neutralizing activities induced by EV71 genotype/sub-genotype A, B0-B4, C1, C2, C4, and C5 viruses using rats. Differences were noted in the cross-neutralization of the 10 sub-genotypes tested but there were generally good levels of cross-neutralization except against genotype A virus, against which neutralization antibody titres (NTAb) where the lowest with NTAbs being the highest against sub-genotype B4. Moreover, NTAb responses induced by C4, B4, C1, and C2 viruses were homogenous, with values of maximum/minimum NTAb ratios (MAX/MIN) against all B and C viruses ranging between 4.0 and 6.0, whereas MAX/MIN values against B3 and A viruses were highly variable, 48.0 and 256.0, respectively. We then dissected the cross-neutralizing ability of sera from infants and children and rats immunized with C4 EV71 vaccines. Cross-neutralizing titers against the 10 sub-genotypes were good in both vaccinated infants and children and rats with the MAX/MIN ranging from 1.8–3.4 and 5.1–7.1, respectively, which were similar to those found in naturally infected patients (2.8). Therefore, we conclude that C4 EV71 vaccines can provide global protection to infants and children against HFMD caused by different sub-genotypes. |
format | Online Article Text |
id | pubmed-8143144 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-81431442021-05-25 Cross-Antigenicity between EV71 Sub-Genotypes: Implications for Vaccine Efficacy Liu, Pei Yuan, Yadi Cui, Bopei Huo, Yaqian Bian, Lianlian Chen, Lei Liu, Siyuan Wang, Chenfei Xu, Yingzhi Tedcastle, Alison Gao, Fan Mao, Qunying Martin, Javier Liang, Zhenglun Viruses Article Enterovirus A-71 (EV71) is a global, highly contagkkious pathogen responsible for severe cases of hand-food-mouth-disease (HFMD). The use of vaccines eliciting cross neutralizing antibodies (NTAbs) against the different circulating EV71 sub-genotypes is important for preventing HFMD outbreaks. Here, we tested the cross-neutralizing activities induced by EV71 genotype/sub-genotype A, B0-B4, C1, C2, C4, and C5 viruses using rats. Differences were noted in the cross-neutralization of the 10 sub-genotypes tested but there were generally good levels of cross-neutralization except against genotype A virus, against which neutralization antibody titres (NTAb) where the lowest with NTAbs being the highest against sub-genotype B4. Moreover, NTAb responses induced by C4, B4, C1, and C2 viruses were homogenous, with values of maximum/minimum NTAb ratios (MAX/MIN) against all B and C viruses ranging between 4.0 and 6.0, whereas MAX/MIN values against B3 and A viruses were highly variable, 48.0 and 256.0, respectively. We then dissected the cross-neutralizing ability of sera from infants and children and rats immunized with C4 EV71 vaccines. Cross-neutralizing titers against the 10 sub-genotypes were good in both vaccinated infants and children and rats with the MAX/MIN ranging from 1.8–3.4 and 5.1–7.1, respectively, which were similar to those found in naturally infected patients (2.8). Therefore, we conclude that C4 EV71 vaccines can provide global protection to infants and children against HFMD caused by different sub-genotypes. MDPI 2021-04-21 /pmc/articles/PMC8143144/ /pubmed/33919184 http://dx.doi.org/10.3390/v13050720 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Liu, Pei Yuan, Yadi Cui, Bopei Huo, Yaqian Bian, Lianlian Chen, Lei Liu, Siyuan Wang, Chenfei Xu, Yingzhi Tedcastle, Alison Gao, Fan Mao, Qunying Martin, Javier Liang, Zhenglun Cross-Antigenicity between EV71 Sub-Genotypes: Implications for Vaccine Efficacy |
title | Cross-Antigenicity between EV71 Sub-Genotypes: Implications for Vaccine Efficacy |
title_full | Cross-Antigenicity between EV71 Sub-Genotypes: Implications for Vaccine Efficacy |
title_fullStr | Cross-Antigenicity between EV71 Sub-Genotypes: Implications for Vaccine Efficacy |
title_full_unstemmed | Cross-Antigenicity between EV71 Sub-Genotypes: Implications for Vaccine Efficacy |
title_short | Cross-Antigenicity between EV71 Sub-Genotypes: Implications for Vaccine Efficacy |
title_sort | cross-antigenicity between ev71 sub-genotypes: implications for vaccine efficacy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8143144/ https://www.ncbi.nlm.nih.gov/pubmed/33919184 http://dx.doi.org/10.3390/v13050720 |
work_keys_str_mv | AT liupei crossantigenicitybetweenev71subgenotypesimplicationsforvaccineefficacy AT yuanyadi crossantigenicitybetweenev71subgenotypesimplicationsforvaccineefficacy AT cuibopei crossantigenicitybetweenev71subgenotypesimplicationsforvaccineefficacy AT huoyaqian crossantigenicitybetweenev71subgenotypesimplicationsforvaccineefficacy AT bianlianlian crossantigenicitybetweenev71subgenotypesimplicationsforvaccineefficacy AT chenlei crossantigenicitybetweenev71subgenotypesimplicationsforvaccineefficacy AT liusiyuan crossantigenicitybetweenev71subgenotypesimplicationsforvaccineefficacy AT wangchenfei crossantigenicitybetweenev71subgenotypesimplicationsforvaccineefficacy AT xuyingzhi crossantigenicitybetweenev71subgenotypesimplicationsforvaccineefficacy AT tedcastlealison crossantigenicitybetweenev71subgenotypesimplicationsforvaccineefficacy AT gaofan crossantigenicitybetweenev71subgenotypesimplicationsforvaccineefficacy AT maoqunying crossantigenicitybetweenev71subgenotypesimplicationsforvaccineefficacy AT martinjavier crossantigenicitybetweenev71subgenotypesimplicationsforvaccineefficacy AT liangzhenglun crossantigenicitybetweenev71subgenotypesimplicationsforvaccineefficacy |